Exelixis (EXEL) Income from Continuing Operations (2010 - 2026)
Exelixis' (EXEL) quarterly Income from Continuing Operations came in at 210467000.0 in Q2 2026, up 31.86% year-on-year from 159616000.0 in Q2 2025, and down 13.93% quarter-over-quarter from 244528000.0 in Q1 2026.
Exelixis (EXEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Exelixis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 210467000.0 for Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 31.86% year-over-year to 210467000.0 in Q2 2026; TTM through Apr 2026 was 833421000.0, a 29.5% increase from a year earlier, with the FY2026 full-year figure at 782570000.0, up 50.13% from the prior year.
- Income from Continuing Operations slipped to 210467000.0 in Q2 2026 per EXEL's latest filing, from 244528000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 244528000.0 in Q1 2026 and bottomed at 30173000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 85518000.0 (2023), against an average of 112020647.06.
- Across the five-year window, Income from Continuing Operations plunged 131.71% in 2022 and soared 11232.66% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 30173000.0 in 2022, then surged by 383.43% to 85518000.0 in 2023, then jumped by 37.95% to 117973000.0 in 2024, then jumped by 64.09% to 193578000.0 in 2025, then increased by 8.72% to 210467000.0 in 2026.
- Per Business Quant, the three latest EXEL Income from Continuing Operations figures stand at 210467000.0 (Q2 2026), 244528000.0 (Q1 2026), and 193578000.0 (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 210.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 210.47 Mn |
| Jan 2, 2026 | 244.53 Mn |
| Oct 3, 2025 | 193.58 Mn |
| Jul 4, 2025 | 184.85 Mn |
| Apr 4, 2025 | 159.62 Mn |
| Jan 3, 2025 | 139.86 Mn |
| Sep 27, 2024 | 117.97 Mn |
| Jun 28, 2024 | 226.12 Mn |
| Mar 29, 2024 | 37.32 Mn |
| Dec 29, 2023 | 85.52 Mn |
| Sep 29, 2023 | 1.04 Mn |
| Jun 30, 2023 | 81.18 Mn |
| Mar 31, 2023 | 40.03 Mn |
| Dec 30, 2022 | -30.17 Mn |
| Sep 30, 2022 | 73.21 Mn |
| Jul 1, 2022 | 70.67 Mn |
| Apr 1, 2022 | 68.57 Mn |
| Dec 31, 2021 | 95.17 Mn |
| Oct 1, 2021 | 38.20 Mn |
| Jul 2, 2021 | 96.09 Mn |